Apolipoprotein E Polymorphism in Hemodialyzed Patients and Healthy Controls |
| |
Authors: | Jaroslav A. Hubacek Silvie Bloudickova Ruzena Kubinova Hynek Pikhart Ondrej Viklicky Martin Bobak |
| |
Affiliation: | 1. Institute for Clinical and Experimental Medicine, CEM, Laboratory for Molecular Genetics, Videnska 1958/9, Prague 4, 14021, Czech Republic 2. Third Internal Department, First Medical Faculty, Charles University, Prague, Czech Republic 3. Cardiovascular Research Centre, Prague, Czech Republic 4. National Institute of Public Health, Prague, Czech Republic 5. Department of Epidemiology and Public Health, University College London, London, UK
|
| |
Abstract: | A possible association between end-stage renal disease (ESRD) and apolipoprotein E (APOE) polymorphism was found in some but not all studies. We have analyzed the APOE genotypes in 995 hemodialyzed patients (cases) and a sample of 6242 healthy individuals (controls) in the Czech Republic. There was a statistically significant difference in the frequency of APOE alleles between cases and controls, with more carriers of the APOE2 allele in ESRD patients (15.9%) than in controls (12.2%) (P = 0.005). The odds ratio of ESRD for the APOE2 allele, compared with APOE3E3 homozygotes, was 1.37 (95% confidence interval 1.13–1.67). The strength of the association increased with the time spent on hemodialysis: the odds ratio of all-cause ESRD in patients dialyzed for eight or more years was 1.27 (0.94–1.71), for 1–8 years 1.41 (1.09–1.81), and less than 1 year (nonsurvivors) 1.94 (0.88–4.18). This study suggests that the APOE2 allele is a possible genetic risk factor for all-cause ESRD in Caucasians. |
| |
Keywords: | |
本文献已被 SpringerLink 等数据库收录! |
|